Protocol Ledger

NCT07253285 · Phase III · RECRUITING

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Interventional Phase III clinical trial protocol NCT07253285 sponsored by Novo Nordisk in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-08 Enrollment: 460 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07253285
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)460 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07253285
Protocol FieldVerified Registry Value
NCT IdentifierNCT07253285
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment460 participants (ESTIMATED)
Registered Start Date2026-01-08
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI